Patient Information Leaflet
Latuda 18.5 mg Film-Coated Tablets
Latuda 37 mg Film-Coated Tablets
Latuda 74 mg Film-Coated Tablets
Lurasidone
Read this leaflet carefully before you start taking this medicine, because
it contains important information for you.
Latuda contains the active substance lurasidone and belongs to a group of medications called antipsychotics. It is used to treat the symptoms of schizophrenia in adults (18 years of age and older) andadolescents aged 13 to 17 years. Lurasidone acts by blocking the brain receptors on which dopamine and serotonin act. Dopamine and serotonin are neurotransmitters (substances that allow nerve cells to communicate with each other) that are involved in the symptoms of schizophrenia. By blocking these receptors, lurasidone helps to normalize brain activity, reducing the symptoms of schizophrenia.
Schizophrenia is a disorder characterized by symptoms such as hearing, seeing, or feeling things that do not exist, holding false beliefs, excessive suspicion, withdrawal, incoherent speech and behavior, and lack of emotions. People who suffer from this disorder may feel depressed, anxious, guilty, or tense. This medication is used to improve their schizophrenia symptoms.
Warnings and precautions
The full effect of this medication may take several days or even weeks to appear.
Consult your doctor if you have any doubts about this medication.
Consult your doctor or pharmacist before taking this medication or during treatment, especially if:
If you meet any of these conditions, consult your doctor, as your doctor may need to adjust your dose, monitor you more closely, or discontinue Latuda treatment.
Children and adolescents
Do not administer to children under 13 years old.
Other medications and Latuda
Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any other medication. This is especially important if you are taking:
Inform your doctor if you are taking any of these medications, as you may need to change the dose of that medication during Latuda treatment.
The following medications may increase the concentration of lurasidone in your blood:
The following medications may decrease the concentration of lurasidone in your blood:
Inform your doctor if you are taking any of these medications, as you may need to change your Latuda dose.
Latuda with food, drinks, and alcohol
Avoid consuming alcohol while taking this medication, as it will have a negative additive effect.
Do not drink grapefruit juice while taking this medication. Grapefruit may affect the action of this medication.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, or think you may be pregnant or plan to become pregnant, consult your doctor or pharmacist before using this medication.
Do not take this medication during pregnancy unless your doctor has agreed to it.
If your doctor decides that the potential benefits of treatment during pregnancy outweigh the potential risk to the unborn child, your doctor will closely monitor your child after birth. This is because newborns of mothers who have used lurasidone in the last trimester (last three months) of pregnancy may experience the following symptoms:
If your child develops any of these symptoms, consult your doctor.
The passage of lurasidone into breast milk is unknown. Inform your doctor if you are breastfeeding your child or plan to do so.
Driving and operating machinery
During treatment with this medication, you may experience drowsiness, dizziness, and vision problems (see section 4, Possible side effects). Do not drive or operate machinery until you know that this medication does not affect you negatively.
Latuda contains sodium
Each tablet contains less than 1 mmol of sodium (23 mg), making it essentially "sodium-free".
Follow exactly the administration instructions for this medication as indicated by your doctor or pharmacist. If in doubt, ask your doctor or pharmacist again.
Your dose will be decided by your doctor and may depend on:
Adults (18 years or older)
The recommended initial dose is 37 mg once a day.
Your doctor may increase or decrease the dose within the range of 18.5 mg to 148 mg once a day. The maximum dose should not exceed 148 mg once a day.
Adolescents 13 to 17 years
The recommended initial dose is 37 mg of lurasidone once a day.
The dose may be increased or decreased by your doctor within the dose range of 37 to 74 mg once a day. The maximum daily dose should not exceed 74 mg.
How to Take Latuda
Swallow the entire tablet with water to mask its bitter taste. Take the dose regularly every day at the same time to make it easier to remember. Take this medication with food or just after eating, as this helps the body absorb the medication and allows it to work better.
If You Take More Latuda Than You Should
If you take more of this medication than you should, consult your doctor immediately.
You may experience drowsiness, fatigue, abnormal body movements, difficulty staying upright and walking, low blood pressure-related dizziness, and abnormal heartbeats.
If You Forget to Take Latuda
Do not take a double dose to make up for missed doses. If you forget to take a dose, take the next dose on the following day after the missed dose. If you forget two or more doses, consult your doctor.
If You Stop Taking Latuda
If you stop taking this medication, you will lose its effects. Do not stop taking the medication unless your doctor tells you to, as symptoms may reappear.
If you have any other questions about using this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
Seek medical attentionimmediately if you notice any of the following symptoms:
Also, the following side effects may appear in adults:
Very common (may affect more than 1 in 10 people):
Common (may affect up to 1 in 10 people):
Uncommon (may affect up to 1 in 100 people):
blood tests
Rare (may affect up to 1 in 1,000 people):
Unknown frequency (cannot be estimated from available data):
muscle, tremor, drowsiness, respiratory or feeding problems
In elderly people with dementia, there has been a small increase in the number of deaths in patients taking antipsychotic medications compared to those not taking them.
In adolescents, the following side effects may appear:
Very common (may affect more than 1 in 10 people):
Common (may affect up to 1 in 10 people):
Uncommon (may affect up to 1 in 100 people):
Reporting of side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the national notification system included in theAppendix V.By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the packaging and blister after CAD or EXP. The expiration date is the last day of the month indicated.
Store in the original packaging to protect it from light.
Medications should not be disposed of through drains or trash. Ask your pharmacist how to dispose of the containers and medications you no longer need. By doing so, you will help protect the environment.
Each 18.5 mg tablet contains hydrochloride equivalent to 18.6 mg of lurasidone.
Each 37 mg tablet contains hydrochloride equivalent to 37.2 mg of lurasidone.
Each 74 mg tablet contains hydrochloride equivalent to 74.5 mg of lurasidone.
hypromellose, magnesium stearate (E 470b), titanium dioxide (E171), macrogol, yellow iron oxide (E172) (present in 74 mg tablets), indigotin (E132) (present in 74 mg tablets), and carnauba wax (E903).
Appearance of the product and contents of the package
Latuda film-coated tablets are available in pack sizes containing 14 x 1, 28 x 1, 30 x 1, 56 x 1, 60 x 1, 90 x 1, or 98 x 1 tablets in pre-cut, unit-dose blisters of aluminum/aluminum.
Only some pack sizes may be marketed.
Marketing Authorization Holder
Aziende Chimiche Riunite Angelini Francesco – A.C.R.A.F. S.p.A.
Viale Amelia 70, 00181
Rome - Italy
Responsible for manufacturing
Aziende Chimiche Riunite Angelini Francesco ACRAF SPA
Via Vecchia del Pinocchio, 22 60100
Ancona (AN), Italy
Millmount Healthcare Ltd.
Block-7, City North Business Campus,
Stamullen, Co. Meath, K32 YD60,
Ireland
For more information about this medicine, please contact the local representative of the marketing authorization holder:
Belgium/ België/ Belgien | Lithuania/ Lietuva |
Bulgaria/ ???????? ????????? ????? ???????? ???? | Luxembourg/ Luxemburg CNX Therapeutics Netherlands B.V. |
Czech Republic/ Ceská republika Angelini Pharma Ceská republika s.r.o. | Hungary/ Magyarország Angelini Pharma Magyarország Kft |
Denmark/ Danmark CNX Therapeutics Netherlands B.V.[email protected] | Malta CNX Therapeutics Netherlands B.V.[email protected] |
Germany/ Deutschland CNX Therapeutics Netherlands B.V.[email protected] | Netherlands/ Nederland CNX Therapeutics Netherlands B.V. |
Estonia/ Eesti CNX Therapeutics Netherlands B.V.[email protected] | Norway/ Norge CNX Therapeutics Netherlands B.V.[email protected] |
Greece/ Ελλ?δα Angelini Pharma Hellas Μονοπρ?σωπη ABEE | Austria/ Österreich Angelini Pharma Österreich GmbH |
Spain/ España ANGELINI PHARMA ESPAÑA, S.L. Tel: + 34 93 253 45 00 | Poland/ Polska Angelini Pharma Polska Sp. z o.o. |
France CNX Therapeutics Netherlands B.V. | Portugal Angelini Pharma Portugal, Unipessoal Lda |
Croatia/ Hrvatska Aziende Chimiche Riunite Angelini Francesco – A.C.R.A.F. S.p.A. Tel: + 39 06 78 0531 | Romania/ România Angelini Pharmaceuticals România SRL |
Ireland CNX Therapeutics Netherlands B.V. | Slovenia/ Slovenija Bonifar d.o.o. Tel: + 386 1 235 0490 |
Iceland/ Ísland CNX Therapeutics Netherlands B.V.[email protected] | Slovak republic/ Slovenská republika Angelini Pharma Slovenská republika s.r.o. |
Italy/ Italia Angelini S.p.A. Tel: + 39 06 78 0531 | Suomi/ Finland CNX Therapeutics Netherlands B.V. |
Cyprus/Κ?προς Angelini Pharma Hellas Μονοπρ?σωπη ABEE | Sweden/ Sverige CNX Therapeutics Netherlands B.V. |
Latvia/ Latvija CNX Therapeutics Netherlands B.V.[email protected] | Northern Ireland CNX Therapeutics Netherlands B.V. |
Last updated date of this leaflet:02/12/2021
For detailed information about this medicine, please visit the European Medicines Agency website:http://www.ema.europa.eu.
Средняя цена на Latuda 74 mg comprimidos recubiertos con pelicula в июль, 2025 года составляет около 37.84 евро. Финальная стоимость может зависеть от региона, конкретной аптеки и рецептурного статуса. Для точной информации лучше проверить онлайн или в ближайшей аптеке.
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.